Electrophysiological Effects of Tipranavir Co-administered With Ritonavir on the QT Interval in Healthy Female and Male Subjects

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To demonstrate that tipranavir (TPV) co-administered with ritonavir (RTV) does not affect the QT interval more than placebo co-administered with ritonavir

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Moxifloxacin; Norgestimate, ethinyl estradiol drug combination; Ritonavir; Tipranavir

Criteria

Inclusion Criteria:

1. Healthy female and male volunteers as determined by the results of screening according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (BP, HR), 12-lead ECG, clinical laboratory tests

2. Age ≥ 18 and Age ≤ 55 years

3. BMI ≥ 18.5 and BMI ≤ 29.9 kg/m2 (Body Mass Index)

4. Signed and dated written informed consent prior to admission to the study in accordance with GCP and the local legislation

Exclusion Criteria:

1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders

2. Gastrointestinal tract surgery (except appendectomy)

3. Diseases of the central nervous system (such as epilepsy, seizures) or psychiatric disorders or neurological disorders

4. History of relevant orthostatic hypotension, fainting spells or blackouts.

5. Relevant acute, chronic or active chronic infections (e.g. hepatitis, HIV).

6. History of allergy/hypersensitivity (including drug allergies) that are deemed relevant to the trial as judged by the investigator

7. Intake of drugs with a long half-life (>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial

8. Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial

9. Participation in another trial with an investigational drug within two months prior to administration or during the trial

10. Smoker (more than 10 cigarettes/day or 3 cigars/day or 3 pipes/day)

11. Inability to refrain from smoking on trial days

12. Alcohol abuse (more than 60 g/day)

13. Drug abuse

14. Veins unsuited for i.v. puncture on either arm (e.g. veins which are difficult to locate, access or puncture, veins with a tendency to rupture during or after puncture)

15. Blood donation (more than 100 mL within four weeks prior to administration or during the trial)

16. History of any bleeding disorder or acute blood coagulation defect

17. Hypersensitivity to ritonavir, moxifloxacin and/or related drugs of these classes

18. History of Glucose-6-phosphate-deficiency

19. Excessive physical activities (within one week prior to trial or during the trial)

20. Any laboratory value outside the reference range that is of clinical relevance

21. A history of additional risk factors for torsade de pointes (TdP) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)

22. Heart rate at screening of > 80 bpm or < 45 bpm

23. Any screening ECG value outside of the reference range of clinical relevance including, but not limited to PR interval > 240 ms, QRS interval > 120 ms, QTcB or QTcF > 450 ms, or QT (uncorrected) > 470 ms

24. Inability to comply with the dietary regimen of the study centre

For female subjects:

25. Pregnancy

26. Positive pregnancy test

27. No adequate contraception (adequate contraception e.g. sterilisation, intrauterine pessary (IUP) or oral contraception not containing ethinyl estradiol)

28. Oral contraception containing ethinyl estradiol without the use of an additional barrier method

29. Hormone replacement containing ethinyl estradiol

30. Inability to maintain this adequate contraception during the whole study period

31. Lactation period